LIFECORE BIOMEDICAL, INC. \DE\ (LFCR)

Data as of Jun 8, 2026, from SEC Form 4 filings.

No open-market insider trades (90d)Watch LFCR

See up to 3 months of LFCR. The 7-day demo opens the 1M and 3M ranges and puts LFCR on your watchlist.

Latest LFCR insider trades

Aron R. English
Open-market sale$649K
May 23, 2025
Aron R. English
Open-market sale$7.41M
May 27, 2025

About LIFECORE BIOMEDICAL, INC. \DE\ (LFCR)

The SEC lists LIFECORE BIOMEDICAL, INC. \DE\ under CIK 0001005286, in pharmaceutical preparations. We track it alongside the rest of the Health Care sector.

Sector: Health Care

SEC filings for LFCR on EDGAR

LFCR Form 4 activity by transaction type, last 90 days

No Form 4 activity for LFCR in the last 90 days.

LFCR insider transactions (Form 4)

34 Form 4 filings on record, the earliest from Oct 7, 2024, newest first. Filing history page 1 of 2.

Date	Insider	Transaction	Security	Shares	Price	Value
Jun 4, 2026	Christopher S. Kiper - Director	Grant or award	Common Stock	25,907^{footnote F2,F3}	-^{footnote F2,F3}	-
Footnote F2 (price, shares): The restricted stock units ("RSUs") convert into Common Stock of the Issuer on a 1 for 1 basis. Footnote F3 (price, shares): Vests on earlier of June 4, 2027 or the date of the annual meeting of stockholders of the Issuer first held in calendar year 2027 (provided such date is no less than 50 weeks from June 4, 2026).
Jun 4, 2026	Nelson Obus - Director	Grant or award	Common Stock	25,907	-^{footnote F1,F2}	-
Footnote F1 (price): The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. Footnote F2 (price): Vests on earlier of June 4, 2027 or the date of the annual meeting of stockholders of the Company first held in calendar year 2027 (provided such date is no less than 50 weeks from June 4, 2026).
Jun 4, 2026	Jason Aryeh - Director	Grant or award	Common Stock	25,907	-^{footnote F1,F2}	-
Footnote F1 (price): The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. Footnote F2 (price): Vests on earlier of June 4, 2027 or the date of the annual meeting of stockholders of the Company first held in calendar year 2027 (provided such date is no less than 50 weeks from June 4, 2026).
Jun 4, 2026	Joshua Schechter - Director	Grant or award	Common Stock	25,907	-^{footnote F1,F2}	-
Footnote F1 (price): The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. Footnote F2 (price): Vests on earlier of June 4, 2027 or the date of the annual meeting of stockholders of the Company first held in calendar year 2027 (provided such date is no less than 50 weeks from June 4, 2026).
Jun 4, 2026	Matthew E. Korenberg - Director	Grant or award	Common Stock	25,907	-^{footnote F1,F2}	-
Footnote F1 (price): The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. Footnote F2 (price): Vests on earlier of June 4, 2027 or the date of the annual meeting of stockholders of the Company first held in calendar year 2027 (provided such date is no less than 50 weeks from June 4, 2026).
Jun 4, 2026	Humberto Calheiros Antunes - Director	Grant or award	Common Stock	25,907	-^{footnote F1,F2}	-
Footnote F1 (price): The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. Footnote F2 (price): Vests on earlier of June 4, 2027 or the date of the annual meeting of stockholders of the Company first held in calendar year 2027 (provided such date is no less than 50 weeks from June 4, 2026).
Jun 4, 2026	Paul Harold Johnson - Director	Grant or award	Common Stock	25,907	-^{footnote F1,F2}	-
Footnote F1 (price): The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. Footnote F2 (price): Vests on earlier of June 4, 2027 or the date of the annual meeting of stockholders of the Company first held in calendar year 2027 (provided such date is no less than 50 weeks from June 4, 2026).
Jun 4, 2026	Lovas Katrina Houde - Director	Grant or award	Common Stock	25,907	-^{footnote F1,F2}	-
Footnote F1 (price): The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. Footnote F2 (price): Vests on earlier of June 4, 2027 or the date of the annual meeting of stockholders of the Company first held in calendar year 2027 (provided such date is no less than 50 weeks from June 4, 2026).
May 20, 2026	Paul Josephs - Officer	Tax withholding / forfeiture	Common Stock	40,413^{footnote F1}	$4.57	$185K
Footnote F1 (shares): Represents number of shares withheld by the issuer to satisfy applicable tax withholding obligations in connection with the vesting and settlement of an RSU vesting.
Apr 14, 2026	Thomas D. Salus - Officer	Tax withholding / forfeiture	Common Stock	24,645^{footnote F1}	$5.20	$128K
Footnote F1 (shares): Represents number of shares withheld by the issuer to satisfy applicable tax withholding obligations in connection with the vesting and settlement of an RSU vesting.
Mar 2, 2026	Thomas D. Salus - Officer	Grant or award	Common Stock	30,000	-^{footnote F1,F2}	-
Footnote F1 (price): The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. Footnote F2 (price): Restricted Stock Units will vest on the 3rd anniversary of the grant date.
Sep 3, 2025	Ryan David Lake - Officer	Tax withholding / forfeiture	Common Stock	22,932	$7.71	$177K
Jul 15, 2025	Nelson Obus - Director	Grant or award	Common Stock	19,506	-	-
Jul 15, 2025	Paul Harold Johnson - Director	Grant or award	Common Stock	19,506	-	-
Jul 15, 2025	Jason Aryeh - Director	Grant or award	Common Stock	19,506	-	-
Jul 15, 2025	Matthew E. Korenberg - Director	Grant or award	Common Stock	19,506	-	-
Jul 15, 2025	Humberto Calheiros Antunes - Director	Grant or award	Common Stock	19,506	-	-
Jul 15, 2025	Joshua Schechter - Director	Grant or award	Common Stock	19,506	-	-
Jul 15, 2025	Lovas Katrina Houde - Director	Grant or award	Common Stock	19,506	-	-
Jul 15, 2025	Christopher S. Kiper - Director	Grant or award	Common Stock	19,506	-	-
Jul 8, 2025	Thomas D. Salus - Officer	Option exercise	Common Stock	37,000	-	-
Jul 8, 2025	Thomas D. Salus - Officer	Tax withholding / forfeiture	Common Stock	11,022	$8.19	$90K
Jul 8, 2025	Thomas D. Salus - Officer	Option exercise	Performance-Based Restricted Stock Units	37,000	-	-
Jul 8, 2025	Ryan David Lake - Officer	Option exercise	Common Stock	75,000	-	-
Jul 8, 2025	Ryan David Lake - Officer	Tax withholding / forfeiture	Common Stock	32,806	$8.19	$269K
Jul 8, 2025	Ryan David Lake - Officer	Option exercise	Performance-Based Restricted Stock Units	75,000	-	-
Jul 8, 2025	Paul Josephs - Officer	Option exercise	Common Stock	150,000	-	-
Jul 8, 2025	Paul Josephs - Officer	Tax withholding / forfeiture	Common Stock	54,857	$8.19	$449K
Jul 8, 2025	Paul Josephs - Officer	Option exercise	Performance-Based Restricted Stock Units	150,000	-	-
May 23, 2025	Aron R. English	Open-market sale	Common Stock	96,137	$6.75	$649K
May 27, 2025	Aron R. English	Open-market sale	Common Stock	1,139,504	$6.50	$7.41M
May 28, 2025	Aron R. English	Open-market sale	Common Stock	150,419	$7.12	$1.07M
May 20, 2025	Paul Josephs - Officer	Tax withholding / forfeiture	Common Stock	21,532	$6.63	$143K
May 13, 2025	Aron R. English	Open-market sale	Common Stock	12,334	$7.00	$86K
May 8, 2025	Aron R. English	Open-market sale	Common Stock	5,098	$7.00	$36K
May 9, 2025	Aron R. English	Open-market sale	Common Stock	700	$7.00	$5K
May 12, 2025	Aron R. English	Open-market sale	Common Stock	45,698	$7.03	$321K
May 5, 2025	Aron R. English	Open-market sale	Common Stock	24,543	$7.08	$174K
May 6, 2025	Aron R. English	Open-market sale	Common Stock	701	$7.05	$5K
May 7, 2025	Aron R. English	Open-market sale	Common Stock	15,847	$7.01	$111K
Apr 14, 2025	Thomas D. Salus - Officer	Grant or award	Common Stock	45,000	-	-
Apr 14, 2025	Thomas D. Salus - Officer	Grant or award	Common Stock	170,000	-	-
Apr 14, 2025	Thomas D. Salus - Officer	Grant or award	Performance-Based Restricted Stock Units	370,000	$0.00	-
Apr 14, 2025	Thomas D. Salus - Officer	Grant or award	Incentive Stock Option (Right to Buy)	210,000	$0.00	-
Dec 6, 2024	Paul Josephs - Officer	Grant or award	Common Stock	38,461	$0.00	-
Dec 6, 2024	Paul Josephs - Officer	Tax withholding / forfeiture	Common Stock	11,769	$7.15	$84K

Recent LFCR Form 8-K filings

Read LFCR company news

Sep 29, 2026Item 1.01, 9.01

Read the filing on SEC EDGAR

Sep 28, 2026Item 1.01, 7.01, 9.01

Read the filing on SEC EDGAR

Aug 5, 2026Item 2.02, 7.01, 9.01

Read the filing on SEC EDGAR

Jul 2, 2026Item 7.01

LFCR insider trading FAQ

What is the latest insider trade for LFCR?

LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) has filed no insider reports in the last 90 days. The most recent on record is dated 2026-06-08. The full record for LFCR runs to 34 Form 4 filings, the earliest from 2024-10-07. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.

How many insiders are buying LFCR stock?

No insider purchases of LFCR were filed in the last 90 days. 4 purchases are on record for this company.

How many insiders are selling LFCR stock?

No insider sales of LFCR were filed in the last 90 days. 10 sales are on record for this company.

Where can I see LFCR SEC filings (Form 4, 10-K, 10-Q, 8-K)?

This page collects LFCR Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.

More Health Care companies with insider activity

Recent insider filings

The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.

Jun 8, 2026 - Christopher S. Kiper view on EDGAR
Jun 5, 2026 - Nelson Obus view on EDGAR
Jun 5, 2026 - Jason Aryeh view on EDGAR
Jun 5, 2026 - Joshua Schechter view on EDGAR
Jun 5, 2026 - Matthew E. Korenberg view on EDGAR
Jun 5, 2026 - Humberto Calheiros Antunes view on EDGAR
Jun 5, 2026 - Paul Harold Johnson view on EDGAR
Jun 5, 2026 - Lovas Katrina Houde view on EDGAR
May 21, 2026 - Paul Josephs view on EDGAR

Related companies with recent insider activity

Learn more

What the Form 4 transaction codes mean: Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
Insider activity in Health Care: Where LFCR's peers are being bought and sold.
Every recent Form 4: The market-wide feed, updated as filings arrive from SEC EDGAR.

Follow LFCR with a 7-day demo

LFCR on your watchlist
Every LFCR Form 4 filing on record
Up to 3 months of LFCR price history
The daily trading plan of ranked insider buys, on a delay, with the plan archive

Start 7-day demoCard required. Your card is never charged for the demo.

Date

Insider

Transaction

Security

Price

Value

Jun 4, 2026

Christopher S. Kiper - Director

Grant or award

Common Stock

25,907^{footnote F2,F3}

-^{footnote F2,F3}

Footnote F2 (price, shares): The restricted stock units ("RSUs") convert into Common Stock of the Issuer on a 1 for 1 basis.
Footnote F3 (price, shares): Vests on earlier of June 4, 2027 or the date of the annual meeting of stockholders of the Issuer first held in calendar year 2027 (provided such date is no less than 50 weeks from June 4, 2026).

Jun 4, 2026

Nelson Obus - Director

Grant or award

Common Stock

25,907

-^{footnote F1,F2}

Footnote F1 (price): The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.
Footnote F2 (price): Vests on earlier of June 4, 2027 or the date of the annual meeting of stockholders of the Company first held in calendar year 2027 (provided such date is no less than 50 weeks from June 4, 2026).

Jun 4, 2026

Jason Aryeh - Director

Grant or award

Common Stock

25,907

-^{footnote F1,F2}

Footnote F1 (price): The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.
Footnote F2 (price): Vests on earlier of June 4, 2027 or the date of the annual meeting of stockholders of the Company first held in calendar year 2027 (provided such date is no less than 50 weeks from June 4, 2026).

Jun 4, 2026

Joshua Schechter - Director

Grant or award

Common Stock

25,907

-^{footnote F1,F2}

Footnote F1 (price): The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.
Footnote F2 (price): Vests on earlier of June 4, 2027 or the date of the annual meeting of stockholders of the Company first held in calendar year 2027 (provided such date is no less than 50 weeks from June 4, 2026).

Jun 4, 2026

Matthew E. Korenberg - Director

Grant or award

Common Stock

25,907

-^{footnote F1,F2}

Footnote F1 (price): The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.
Footnote F2 (price): Vests on earlier of June 4, 2027 or the date of the annual meeting of stockholders of the Company first held in calendar year 2027 (provided such date is no less than 50 weeks from June 4, 2026).

Jun 4, 2026

Humberto Calheiros Antunes - Director

Grant or award

Common Stock

25,907

-^{footnote F1,F2}

Footnote F1 (price): The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.
Footnote F2 (price): Vests on earlier of June 4, 2027 or the date of the annual meeting of stockholders of the Company first held in calendar year 2027 (provided such date is no less than 50 weeks from June 4, 2026).

Jun 4, 2026

Paul Harold Johnson - Director

Grant or award

Common Stock

25,907

-^{footnote F1,F2}

Footnote F1 (price): The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.
Footnote F2 (price): Vests on earlier of June 4, 2027 or the date of the annual meeting of stockholders of the Company first held in calendar year 2027 (provided such date is no less than 50 weeks from June 4, 2026).

Jun 4, 2026

Lovas Katrina Houde - Director

Grant or award

Common Stock

25,907

-^{footnote F1,F2}

Footnote F1 (price): The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.
Footnote F2 (price): Vests on earlier of June 4, 2027 or the date of the annual meeting of stockholders of the Company first held in calendar year 2027 (provided such date is no less than 50 weeks from June 4, 2026).

May 20, 2026

Paul Josephs - Officer

Tax withholding / forfeiture

Common Stock

40,413^{footnote F1}

$4.57

$185K

Footnote F1 (shares): Represents number of shares withheld by the issuer to satisfy applicable tax withholding obligations in connection with the vesting and settlement of an RSU vesting.

Apr 14, 2026

Thomas D. Salus - Officer

Tax withholding / forfeiture

Common Stock

24,645^{footnote F1}

$5.20

$128K

Footnote F1 (shares): Represents number of shares withheld by the issuer to satisfy applicable tax withholding obligations in connection with the vesting and settlement of an RSU vesting.

Mar 2, 2026

Thomas D. Salus - Officer

Grant or award

Common Stock

30,000

-^{footnote F1,F2}

Footnote F1 (price): The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.
Footnote F2 (price): Restricted Stock Units will vest on the 3rd anniversary of the grant date.

Sep 3, 2025

Ryan David Lake - Officer

Tax withholding / forfeiture

Common Stock

22,932

$7.71

$177K

Jul 15, 2025

Nelson Obus - Director

Grant or award

Common Stock

19,506